Nouscom appoints John F McDonald as independent director to its board of directors
5 November 2018 -

Immuno-oncology company Nouscom, a developer of off-the-shelf and personalised neoantigen-based genetic cancer vaccines based on its proprietary technology platform, revealed on Monday that John F McDonald has been appointed to its board of directors, as an independent director.

With over 25 years experience in corporate, legal, business development and venture capital in the pharmaceutical and biotech industries, McDonald has expertise that involves academic institutions and biotech and pharmaceutical companies of all stages, including financing, acquisitions, R&D collaborations and in-licensing agreements, among others, the company stated.

McDonald is currently Corporate VP, Global Business Development at Novo Nordisk.

Previously, he served as VP Business Development at Biogen Inc, managing director at healthcare investment firm MPM Capital and VP Business Development at Millennium Pharmaceuticals.